Please select the option that best describes you:
Would you use pembrolizumab to treat patients with BCG-refractory Ta or T1 NMIBC without CIS?
Answer from: Medical Oncologist at Academic Institution
Pembrolizumab FDA-approved indication includes BCG-unresponsive CIS with or without papillary tumor in patients who refuse or cannot undergo radical cystectomy based on the cohort A of KEYNOTE-057 trial. The question of data extrapolation to BCG-unresponsive Ta or T1 without CIS is a reasonable one....
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The current FDA approval of pembrolizumab is for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo ...